


Subt. Form PTO-1449				Docket Number HYZ-069CN (47508.530)		Application Number 09/837,806	
INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Applicant Agrawal			
				Filing Date April 18, 2001		Group Art Unit 1635	
Sheet	2	OF	3				

A14	Beaucage (1993) "Oligodeoxyribonucleotides Synthesis" in <u>Methods in Molecular Biology</u> , Vol. 20: <u>Protocols for Oligonucleotides and Analogs</u> , (Agrawal, ed.) Humana Press, Totowa, NJ, pp.33-61
A15	Brown (1993) "A Brief History of Oligonucleotide Synthesis" in <u>Methods in Molecular Biology</u> , Vol. 20: <u>Protocols for Oligonucleotides and Analogs</u> , pp. 1-17
A16	Craig et al. (1997) "Patent strategies in the antisense oligonucleotide based therapeutic approach" <i>Exp. Opin. Ther. Patents</i> 7(10):1175-1182
A17	Database CAS Registry (2003), (Date of entry: 1997), Registry number 193635-63-1
A18	Froehler (1993) "Oligodeoxynucleotide Synthesis," <u>Methods in Molecular Biology</u> , Vol. 20: <u>Protocols for Oligonucleotides and Analogs</u> (Agrawal, ed.) Humana Press, Totowa, NJ, pp. 63-80
A19	Galdieri et al. (1999) "Antisense Oligonucleotides as Therapeutic Agents" <i>J. Cell. Physiol.</i> 181:251-257
A20	Gewirtz et al. (1996) "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver On Its Promise," <i>Proc. Natl. Acad. Sci. USA</i> 93:3161-3163
A21	Goodchild et al. (1988) "Inhibition of Human Immunodeficiency Virus Replication by Antisense Oligodeoxynucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 85:5507-5511
A22	Harrison et al. (1991) "Determination of the Secondary Structure of the Packaging Signal of HIV-1" in <u>RNA Tumor Viruses</u> (Coffin et al., eds.) Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p. 235
A23	Iyer et al. (1995) "A Novel Nucleoside Phosphoramidite Synthon Derived From 1R, 2S-Ephedrine," <i>Tetrahedron: Asymmetry</i> 6(5):1051-1054
A24	Krieg et al. (1995) "CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation," <i>Nature</i> 374:546-549
A25	Lisiewicz et al. (1992) "Specific Inhibition of Human Immunodeficiency Virus Type 1 Replication by Antisense Oligonucleotides: An <i>In Vitro</i> Model for Treatment," <i>Proc. Natl. Acad. Sci. USA</i> 89:11209-11213
A26	Lisiewicz et al. (1993) "Long-Term Treatment of Human Immunodeficiency Virus-Infected Cells with Antisense Oligonucleotide Phosphorothioates," <i>Proc. Natl. Acad. Sci. USA</i> 90:3860-3864
A27	Lisiewicz et al. (1994) "Antisense Oligodeoxynucleotide Phosphorothioate Complementary to Gag mRNA Blocks Replication of Human Immunodeficiency Virus Type 1 in Human Peripheral Blood Cells," <i>Proc. Natl. Acad. Sci. USA</i> 91:7942-7946
A28	Matsukura et al. (1988) "Synthesis of Phosphorothioate Analogues of Oligodeoxyribonucleotides and Their Antiviral Activity Against Human Immunodeficiency Virus (HIV)," <i>Gene</i> 72:343-347
A29	Matsukura et al. (1989) "Regulation of Viral Expression of Human Immunodeficiency Virus <i>In Vitro</i> by an Antisense Phosphorothioate Oligodeoxynucleotide Against <i>rev</i> (<i>art</i> / <i>trs</i>) in Chronically Infected Cells," <i>Proc. Natl. Acad. Sci. USA</i> 86:4244-4248
A30	Matsukura et al. (1991) "A New Concept in AIDS Treatment: An Antisense Approach and Its Current Status Towards Clinical Application," in <u>Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS</u> (Wickstrom, ed.), Wiley-Liss, Inc., pp. 159-178
A31	Meteliev et al. (1998) "HPLC of Oligodeoxyribonucleoside Phosphorothioates", Abstract No. 151268f, <i>Chemical Abstracts</i> , 128(13):272
A32	Meteliev, et al. (1997) "HPLC of Oligodeoxyribonucleoside Phosphorothioates" <i>Russian Journal of Bioorganic Chemistry</i> , 23(9):673-677, Translated from <i>Bioorganicheskaya Khimiya</i> 23(9):742-746
A33	Milligan, et al. (1993) "Current Concepts in Antisense Drug Design", <i>Journal of Medicinal Chemistry</i> , 36(14):1923-1937
A34	Milner et al. (1997) "Selecting Effective Antisense Reagents on Combinatorial Oligonucleotide Arrays," <i>Nature Biotech.</i> 15:537-541
A35	Rojanasakul (1996) "Antisense Oligonucleotide Therapeutics: Drug Delivery and Targeting," <i>Adv. Drug Del. Rev.</i> Vol. 18:115-131
A36	Sarin et al. (1988) "Inhibition of Acquired Immunodeficiency Syndrome Virus by Oligodeoxynucleoside Methylphosphonates," <i>Proc. Natl. Acad. Sci. USA</i> 85:7448-7451
A37	Sonveaux (1994) "Protecting Groups in Oligonucleotide Synthesis," <u>Methods in Molecular Biology</u> , Vol. 26: <u>Protocols for Oligonucleotide Conjugates</u> (Agrawal, ed.), pp. 1-71
A38	Tang et al. (1993) "Self-Stabilized Antisense Oligodeoxynucleotide Phosphorothioates: Properties and Anti-HIV Activity," <i>Nucleic Acids Res.</i> 21(11):2729-2735
A39	Uhlmann et al. (1990) "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chem. Rev.</i> 90(4):543-584

EXAMINER	DATE CONSIDERED
	6/3/04
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

Subt. Form PTO-1449				Docket Number HYZ-069CN (47508.530)		Application Number 09/837,806	
INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Applicant Agrawal			
				Filing Date April 18, 2001		Group Art Unit 1635	
Sheet	1	OF	3				

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
J3	4,309,404	01/05/82	DeNeale et al.			
	4,309,406	01/05/82	Guley et al.			
	4,556,552	12/03/85	Porter et al.			
	4,704,295	11/03/87	Porter et al.			
	5,627,277	05/06/97	Cohen et al.			

Foreign Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
J3	WO 94/08004	04/14/94	PCT				
	WO 95/18813	07/13/95	PCT				
	WO96/12497	05/02/96	PCT				
	WO 97/06662	02/27/97	PCT				
	WO 98/40058	9/17/1998	PCT				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)		
J3	A1	Agrawal et al. (1987) "Oligodeoxynucleoside Methylphosphonates: Synthesis and Enzymic Degradation," <i>Tetrahedron. Lett.</i> 28(31):3539-3542
	A2	Agrawal et al. (1988) "Oligodeoxynucleoside Phosphoramidates and Phosphorothioates as Inhibitors of Human Immunodeficiency Virus," <i>Proc. Natl. Acad. Sci. USA</i> 85:7079-7083
	A3	Agrawal et al. (1989) "Inhibition of Human Immunodeficiency Virus in Early Infected and Chronically Infected Cells by Antisense Oligodeoxynucleotides and Their Phosphorothioate Analogues," <i>Proc. Natl. Acad. Sci. USA</i> 86:7790-7794
	A4	Agrawal (1991) "Antisense Oligonucleotides: A Possible Approach for Chemotherapy of Aids," in <i>Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS</i> , (Wickstrom, ed.) Wiley-Liss, Inc., pp. 143-158
	A5	Agrawal (1992) "Antisense Oligonucleotides as Antiviral Agents," <i>Trends in Biotechnology</i> 10:152-158
	A6	Agrawal et al. (1992) "Cellular Uptake and Anti-HIV Activity of Oligonucleotides and Their Analogs," <i>Gene Regulation: Biology of Antisense RNA and DNA</i> (Erickson and Izant, eds.) Raven Press Ltd., New York, pp. 273-283
	A7	Agrawal, et al. (1992) "GEM*91 - An Antisense Oligonucleotide Phosphorothioate as a Therapeutic Agent for AIDS", <i>Antisense Res. Dev.</i> 2:261-266
	A8	Agrawal et al. (1994) "Potential for HIV-1 Treatment with Antisense Oligonucleotides", <i>J. Biotech. in Healthcare</i> , 1(2):167-182.
	A9	Agrawal, et al. (1995) "Pharmacokinetics of Antisense Oligonucleotides", <i>Clin. Pharmacokinet.</i> 28(1):7-16
	A10	Agrawal et al. (1995) "Absorption, Tissue Distribution and In Vivo Stability in Rats of a Hybrid Antisense Oligonucleotide Following Oral Administration," <i>Biochem. Pharmacol.</i> 50(4):571-576
	A11	Agrawal (1996) "Preface" in <i>Methods in Molecular Medicine: Antisense Therapeutics</i> (Agrawal, ed.) pp. v-vii
	A12	Agrawal, et al. (1998) "Pharmacokinetics and Bioavailability of Antisense Oligonucleotides Following Oral and Colorectal Administrations in Experimental Animals", in <i>Handbook of Experimental Pharmacology</i> , Vol. 131: <i>Antisense Research and Application</i> , Springer-Verlag, pp. 525-543
	A13	Agrawal (1999) "Importance of Nucleotide Sequence and Chemical Modifications of Antisense Oligonucleotides," <i>Biochimica et Biophysica Acta</i> 1489:53-68

EXAMINER J3	DATE CONSIDERED 6/4/04
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

